Mahmoud Mohamed Soliman

Mahmoud Mohamed Soliman

Auto-generated profile, based on publicly available information

Mahmoud Mohamed Soliman

Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, El-Manial, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2007 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MSMahmoud M. Soliman
Mahmoud M. Soliman
TMTamer A. Macky
Tamer A. Macky

12 August 2010 in Ophthalmic Research
Verified
Journal Article
Closed access
TMTamer A. Macky
Tamer A. Macky
NKNoha Khater
Noha Khater
MAMohammad A. Al-Zamil
Mohammad A. Al-Zamil
HFHussein El Fishawy
Hussein El Fishawy
MSMahmoud M. Soliman
Mahmoud M. Soliman
Purpose: To determine the prevalence and determinants of diabetic retinopathy (DR) in patients ≧18 years at the Cairo University and Sixth of October University hospitals. Patients and Methods: This is a cross-sectional survey among known diabetic patients attending diabetic clinics. Patients were randomly selected to complete an interviewer-administered questionnaire and a medical assessment. All patients had a dilated fundus examination for evidence of DR using slit-lamp biomicroscopy. Results: A sample of 1,325 patients was selected with a mean age of 49 years (SD ±12.9). DR was found in 20.5% of patients. Most patients (82%) were not aware of the hazards of diabetes mellitus for the eyes. The prevalence of DR was statistically significantly higher in females (22 vs.17%, p < 0.05), with longer diabetes disease duration (p < 0.001), hypertension (p < 0.001) and absence of hypertension control (p < 0.001), especially proliferative DR. Increasing age and poor glycemic control were associated with a nonsignificant increase in the rate of DR (p = 0.340 and p = 0.444, respectively). Conclusion: The prevalence of DR in our study population is 20.5%. Regular screening is highly recommended for early detection of DR where timely laser photocoagulation is known to reduce the risk of visual loss in these patients.

1 August 2004 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
MSMahmoud M Soliman
Mahmoud M Soliman
TMTamer A Macky
Tamer A Macky
KSKhaled M. Samir
Khaled M. Samir
To assess the efficacy of lidocaine gel, bupivacaine drops, and benoxinate drops as topical anesthetic agents in cataract surgery. Kasr El-Aini Hospital, Cairo University, Cairo, Egypt. This prospective randomized study comprised 90 patients scheduled for routine cataract extraction. Patients were randomized into 3 groups of 30 each based on which anesthetic agent they received: lidocaine 2% gel, bupivacaine 0.5% drops, or benoxinate 0.4% drops. Subjective pain at application of the agent and intraoperatively was quantified by the patients using a verbal pain score (VPS) scale from 0 to 10. The duration of discomfort at application, duration of surgery, rate of supplemental sub-Tenon's anesthesia, and complications were recorded. The mean VPS at application was 2.97, 1.53, and 1.03 in the lidocaine, bupivacaine, and benoxinate groups, respectively; the VPS in the lidocaine group was statistically significantly higher than in the other 2 groups (P<.001). The mean duration of pain at application was 25 seconds, 14 seconds, and 6 seconds in the lidocaine, bupivacaine, and benoxinate groups, respectively, and was statistically significantly higher in the lidocaine group (P<.001). The mean VPS during surgery was 1.6, 4.1, and 7.1 in the lidocaine, bupivacaine, and benoxinate groups; the lidocaine group had a statistically significantly lower mean VPS than the other 2 groups (P<.001). The incidence of supplemental sub-Tenon's injection was 3.3%, 10.0%, and 73.3%, respectively, and was statistically significantly lower in the lidocaine and bupivacaine groups than in the benoxinate group (P<.001). The patients' overall satisfaction was statistically significantly higher in the lidocaine and bupivacaine groups than in the benoxinate group (93.3%, 83.3%, and 33.3%, respectively) (P<.001). Three patients in the lidocaine group had corneal haze at the time of surgery, which was not statistically significant (P>.1). Lidocaine gel was a better topical anesthetic agent than bupivacaine and benoxinate drops. Bupivacaine drops were effective in providing deep topical anesthesia.

1 June 2014 in Experimental Eye Research
Verified
Journal Article
Closed access
KNKhaled Nassar
Khaled Nassar
SGSwaantje Grisanti
Swaantje Grisanti
ATAysegul Tura
Aysegul Tura
JLJulia Lüke
Julia Lüke
MLMatthias Lüke
Matthias Lüke
SGSalvatore Grisanti
Salvatore Grisanti

7 July 2011 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
KNKhaled Nassar
Khaled Nassar
JLJulia Lüke
Julia Lüke
MLMatthias Lüke
Matthias Lüke
MKMahmoud Kamal
Mahmoud Kamal
EEEffat Abd El-Nabi
Effat Abd El-Nabi
SGSalvatore Grisanti
Salvatore Grisanti

1 December 2016 in Retina
Verified
Journal Article
Closed access
MHMostafa M.E. Hamza
Mostafa M.E. Hamza
TMTamer A. Md Macky
Tamer A. Md Macky
MSMohamed Karim Sidky
Mohamed Karim Sidky
GRGaafar Mohamed Ragab
Gaafar Mohamed Ragab
MSMahmoud M. Soliman
Mahmoud M. Soliman
Purpose: To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet's disease. Methods: Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0–4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed at baseline, Day 1 and Week 2, 4, 6, 8, 12, and 18. Optical coherence tomography (OCT) central foveal thickness, fluorescein angiography, and flash electroretinogram were done at baseline and 4, 12, and 18 weeks. Results: Mean baseline logMAR BCVA was 0.94 (20/160), had improved significantly by Week 2 to 0.6 (20/80) (P < 0.0001), and reached 0.36 (20/40) by Weeks 18 with three injections (P < 0.0001). Mean central foveal thickness OCT decreased significantly from baseline 361 μm to 180 μm at the end of follow-up (P < 0.0001). Profound decrease in mean vitreous haze gradings from two to 0.2 by the end follow-up (P < 0.05). There was a significant reduction in the number of patients with vasculitis (15 at baseline to 1 weeks at 18 weeks), retinitis (nine at baseline to none at 4 weeks), and papillitis (two at baseline to none at 4 weeks) (P < 0.05). No significant electrophysiological changes or ocular adverse inflammatory reactions were observed during the study period. Conclusion: Intravitreal infliximab appeared to be safe and effective in treating uveitis in Behcet's disease and should be considered as an alternative to systemic therapies.